The Safety and Tolerability of Atopaxar (E5555) in ... - summitMD.com
The Safety and Tolerability of Atopaxar (E5555) in ... - summitMD.com
The Safety and Tolerability of Atopaxar (E5555) in ... - summitMD.com
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
∆ <strong>in</strong> QTc from basel<strong>in</strong>e to end-<strong>of</strong>-treatment (ms)<br />
LANCELOT-ACS<br />
PDF-XChange Viewer<br />
w w w.docu-track.co m<br />
Click to buy NOW!<br />
<strong>Atopaxar</strong><br />
QTc Interval<br />
PDF-XChange Viewer<br />
w w w.docu-track.co m<br />
Click to buy NOW!<br />
0<br />
-2<br />
Placebo 50mg 100mg 200mg<br />
• Overall shorten<strong>in</strong>g <strong>of</strong> QTc was<br />
seen <strong>in</strong> all study arms from<br />
r<strong>and</strong>omization to end <strong>of</strong><br />
treatment<br />
-4<br />
-6<br />
-4.5<br />
*<br />
-4.9<br />
*<br />
• <strong>The</strong> mean decrease <strong>in</strong> QTc was<br />
greater <strong>in</strong> the placebo group than<br />
the <strong>com</strong>b<strong>in</strong>ed atopaxar group<br />
(P=0.04)<br />
-8<br />
• This effect was dose-dependent<br />
-10<br />
-9.9<br />
• <strong>The</strong>re were no associated cases<br />
<strong>of</strong> syncope or known malignant<br />
arrhythmias<br />
-12<br />
-11.4<br />
P for trend = 0.07<br />
* P
Change language